Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registryBlanca Hernández-Cruz, Lucía Otero-Varela, Mercedes Freire-González, Noemí Busquets-Pérez, Alfredo Javier García González, Manuel Moreno-Ramos, Juan Maria Blanco-Madrigal, Sara Manrique-Arija, Eva Perez-Pampin, Dolores Ruiz-Montesino, Fernando Sánchez-Alonso, Carlos Sanchez-Piedra, Isabel Castrejón,
9 April 2024
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide databaseMarcin Stajszczyk, Izabela Obarska, Slawomir Jeka, Bogdan Batko
16 June 2023
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studiesWalter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, Suresh Sikka, René Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Sławomir Jeka, Radka Moravcová, Vijay Rajendran, Franck-Olivier Le BrunSee the full list of authors
3 May 2023
Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)Luis Fernando Perez-Garcia, Esther Röder, Bouwe P Krijthe, Laura JC Kranenburg-van Koppen, Roxanne van Adrichem, Els Zirkzee, Pieter H Griffioen, Kris Peeters, Marry Lin, Eduard A Struys, Gerrit Jansen, Martijn BA van Doorn, Robert de Jonge, Gert R Dohle, Radboud JEM Dolhain
1 June 2023
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indicationsMark D Russell, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam A Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P Cope, James B Galloway
29 May 2023
Efficacy and safety of emapalumab in macrophage activation syndromeFabrizio De Benedetti, Alexei A Grom, Paul A Brogan, Claudia Bracaglia, Manuela Pardeo, Giulia Marucci, Despina Eleftheriou, Charalampia Papadopoulou, Grant S Schulert, Pierre Quartier, Jordi Antón, Christian Laveille, Rikke Frederiksen, Veronica Asnaghi, Maria BallabioSee the full list of authors
31 March 2023
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trialCelia AJ Michielsens, Nathan den Broeder, Frank HJ van den Hoogen, Elien AM Mahler, Steven Teerenstra, Désirée van der Heijde, Lise M Verhoef, Alfons A den Broeder
14 June 2022
Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancyNafise Ghalandari, Erik Kemper, Ineke (Hubertina) Crijns, Gertjan Wolbink, Theo Rispens, Hieronymus TW Smeele, Radboud JEM Dolhain
7 September 2021
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD studyIngrid Egeland Christensen, Siri Lillegraven, Pawel Mielnik, Gunnstein Bakland, Liz Loli, Joe Sexton, Till Uhlig, Tore K Kvien, Sella A Provan
8 October 2021
Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 allelesVivian E Saper, Michael J Ombrello, Adriana H Tremoulet, Gonzalo Montero-Martin, Sampath Prahalad, Scott Canna, Chisato Shimizu, Gail Deutsch, Serena Y Tan, Elaine F Remmers, Dimitri Monos, Timothy Hahn, Omkar K Phadke, Elaine Cassidy, Ian FergusonSee the full list of authors
17 November 2021
